Breath of life: new test could sniff out gut cancers before they spread

NCT ID NCT07714538

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants provide a breath sample before a scheduled hospital procedure, and researchers check whether the test can reliably tell who has cancer and who does not.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a breath test measuring volatile organic compounds (VOCs)
What this could lead to
If successful, this breath test could enable earlier detection of gastrointestinal cancers, potentially improving treatment outcomes and survival.
What could go wrong
This is a validation study; the test may not prove accurate enough for clinical use, and false positives or negatives could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult Participants who meet the eligibility criteria and are being referred for further specialised investigations within the NHS.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult participants ≥ 18 years old who meet at least one of the following criteria Colorectal arm: 1. Cancer: Histologically-confirmed CRC\* 2. Control: Non-specific abdominal symptoms with normal or benign colonoscopy findings Pancreatic arm: 1. Cancer: Histologically-confirmed PDAC\* 2. Control: Non-specific abdominal symptoms with a radiologically-normal pancreas Oesophagogastric arm: 1. Cancer: Histologically-confirmed OGC\* 2. Control: Non-specific abdominal symptoms with normal or benign upper gastrointestinal endoscopy findings Oesophageal squamous arm: 1. Cancer: Histologically-confirmed OSCC\* 2. Control: Non-specific abdominal symptoms with normal or benign upper gastrointestinal endoscopy findings Liver arm: 1. Cancer: Histologically- or radiologically-confirmed HCC or CCC\* 2. Control: Non-specific abdominal symptoms with a radiologically-normal liver * Patients with suspected cancer (e.g. based on imaging) but who do not have histological confirmation prior to participating in the study may still be recruited and followed up to determine whether or not a diagnosis of cancer was subsequently confirmed. Exclusion Criteria: * Patients who have already received chemotherapy, radiotherapy or surgery for their cancer * History of another cancer (other than non-melanoma skin cancers) within three years * Participants with co-morbidities preventing breath collection * Unable or unwilling to provide informed consent * (For Oesophagogastric arm only): Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid * (For Colorectal arm only): Participants receiving bowel prep in the previous 7 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Imperial College Healthcare NHS Trust

    London, W12 0NN, United Kingdom

  • Liverpool University Hospitals NHS Foundation Trust

    Liverpool, Merseyside, L7 8XP, United Kingdom

  • Maidstone and Tunbridge Wells NHS Trust

    Maidstone, Kent, ME16 9QQ, United Kingdom

  • NHS Greater Glasgow and Clyde

    Glasgow, G12 0XH, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, NW3 2QG, United Kingdom

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Liverpool, L7 8YA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.